[thornjm]

I worry this comment is overly dismissive of criticisms and overly optimistic about potential positives. On medicine topics I think it is important to try remain objective.

1. On DXM being an NMDA antagonist: At high concentration DXM is an NMDA antagonist and AXS-05 does dramatically increases DXM concentration [0] (slide 6). It is not clear to me why we should "ignore anyone" who makes this comparison?

2. On AXS-05 having a wide array of receptor targets: Almost all psychoactive drugs have some affinity for many receptors (just wikipedia any anti-psychotic e.g. [1]). Are any of the targets mentioned clinically significant at therapeutic concentrations?

[0] https://axsometherapeuticsinc.gcs-web.com/static-files/4a508... [1] https://en.wikipedia.org/wiki/Olanzapine

[PragmaticPulp]

> It is not clear to me why we should "ignore anyone" who makes this comparison?

I said that we should ignore people trying to compare this drug to recreational use.

It's likely that NMDA is in play and I'm not suggesting otherwise. I wanted to highlight that DXM has significant affinities for other targets like the serotonin transporter that could also explain the efficacy, so it's a mistake to focus on one receptor as the single answer.